Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Viktor Grünwald; Thomas Powles; Masatoshi Eto; Evgeny Kopyltsov; Sun Young Rha; Camillo Porta; Robert Motzer; Thomas E Hutson; María José Méndez-Vidal; Sung-Hoo Hong; Eric Winquist; Jeffrey C Goh; Pablo Maroto; Tomas Buchler; Toshio Takagi; Joseph E Burgents; Rodolfo Perini; Cixin He; Chinyere E Okpara; Jodi McKenzie; Toni K Choueiri

doi:10.3389/fonc.2023.1343027

Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Front Oncol. 2024 Mar 1:13:1343027. doi: 10.3389/fonc.2023.1343027. eCollection 2023.

Authors

Viktor Grünwald¹, Thomas Powles², Masatoshi Eto³, Evgeny Kopyltsov⁴, Sun Young Rha⁵, Camillo Porta⁶, Robert Motzer⁷, Thomas E Hutson⁸, María José Méndez-Vidal⁹, Sung-Hoo Hong¹⁰, Eric Winquist¹¹, Jeffrey C Goh¹², Pablo Maroto¹³, Tomas Buchler¹⁴, Toshio Takagi¹⁵, Joseph E Burgents¹⁶, Rodolfo Perini¹⁷, Cixin He¹⁸, Chinyere E Okpara¹⁹, Jodi McKenzie²⁰, Toni K Choueiri²¹

Affiliations

¹ Clinic for Medical Oncology and Clinic for Urology, University Hospital Essen, Essen, Germany.
² Barts Cancer Institute and the Royal Free Hospital, Queen Mary University of London, London, United Kingdom.
³ Department of Urology, Kyushu University, Fukuoka, Japan.
⁴ State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia.
⁵ Department of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
⁶ Department of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', Bari, Italy.
⁷ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
⁸ Medical Oncology, Texas Oncology, Dallas, TX, United States.
⁹ Department of Oncology, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain.
¹⁰ Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
¹¹ Department of Oncology, University of Western Ontario, London, ON, Canada.
¹² ICON Research, South Brisbane & University of Queensland, St Lucia, QLD, Australia.
¹³ Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
¹⁴ Department of Oncology, Charles University and Thomayer University Hospital, Prague, Czechia.
¹⁵ Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
¹⁶ Global Clinical Development, Merck & Co., Inc., Rahway, NJ, United States.
¹⁷ Clinical Research, Merck & Co., Inc., Rahway, NJ, United States.
¹⁸ Biostatistics, Eisai Inc., Nutley, NJ, United States.
¹⁹ Clinical Research, Eisai Ltd., Hatfield, United Kingdom.
²⁰ Clinical Research, Eisai Inc., Nutley, NJ, United States.
²¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2023.1223282.].

Keywords: bone metastases; lenvatinib; liver metastases; lung metastases; pembrolizumab; renal cell carcinoma; sarcomatoid histology; sunitinib.

Publication types

Published Erratum